Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...

Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...

As the number of patients with multiple myeloma and lymphoma treated with CAR-T therapy increases, health systems are ...

Clinicians are moving toward managing mild (Grade 1) cytokine release syndrome on an outpatient basis. The most common and ...

The use of an older medication at the time of surgery can reduce the need for red blood cell transfusions, according to a ...

A modified immunotherapy regimen for advanced melanoma showed a 49% response rate and extended median overall survival to 42 ...

The CAR T Vision Steering Committee members wish to double the number of eligible patients receiving chimeric antigen ...

Expert discusses how emerging technologies like at-home testing and AI are redefining CKD screening and prevention for the ...

Expert discusses how chronic kidney disease ( CKD) and cardiovascular disease are interlinked, requiring proactive management ...

Expert discusses how health care teams must empower patients through ongoing dialogue, emphasizing shared decision-making and ...

Jaypirca (pirtobrutinib) improved progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) when compared with bendamustine ...